Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

The latest product approvals and launches.

You may also be interested in...



Financings In Brief

GenMark Diagnostics prices $42 million secondary offering. Oxford Immunotec raises $28 million for TB test commercialization efforts. Benvenue Medical gets $25 million for spinal devices. More financings.

New Products In Brief

Recent product approvals and launches

DFine's STAR Spinal Tumor Ablation System To Hit U.S. Market In Q4

DFine plans to begin a gradual commercial launch late this year of its STAR system, designed to help cancer patients suffering from painful metastases in the spine.

Table

View full table

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Minute Insight: Enovis Buys Lima To Great Billion-Dollar Recon Business

Contingency Planning: Guidance Doc Details Handling Clinical Trials During Emergencies

ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

Theradaptive Receives $7.4M From DoD, Advances Human Trials With ‘Paint-Like’ Regenerative Therapeutic

See All
UsernamePublicRestriction

Register

MT031121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By